| Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two … MCS Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M ... Lancet 385 (10030), 1816, 2015 | 692* | 2015 |
| Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. MP Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal ... Clin Infect Dis 48 (1), 633-9, 2009 | 227 | 2009 |
| Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis DHS Tan, MW Hull, D Yoong, C Tremblay, P O’byrne, R Thomas, J Kille, ... Cmaj 189 (47), E1448-E1458, 2017 | 197 | 2017 |
| Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection MA Jenabian, M El-Far, K Vyboh, I Kema, CT Costiniuk, R Thomas, ... The Journal of infectious diseases 212 (3), 355-366, 2015 | 134 | 2015 |
| Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients T Walter, B Lebouche, P Miailhes, L Cotte, C Roure, I Schlienger, C Trepo Clinical infectious diseases 43 (6), 787-790, 2006 | 110 | 2006 |
| Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients É Vuille-Lessard, B Lebouché, L Lennox, JP Routy, CT Costiniuk, ... Aids 30 (17), 2635-2643, 2016 | 103 | 2016 |
| Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis T Pembroke, M Deschenes, B Lebouché, A Benmassaoud, M Sewitch, ... Journal of hepatology 67 (4), 801-808, 2017 | 102 | 2017 |
| Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART … P Miailhes, MA Trabaud, P Pradat, B Lebouché, M Chevallier, ... Clinical Infectious Diseases 45 (5), 624-632, 2007 | 92 | 2007 |
| Circulating (1→ 3)-β-D-glucan is associated with immune activation during human immunodeficiency virus infection V Mehraj, R Ramendra, S Isnard, FP Dupuy, R Ponte, J Chen, I Kema, ... Clinical Infectious Diseases 70 (2), 232-241, 2020 | 87 | 2020 |
| Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-cell counts W Cao, V Mehraj, B Trottier, JG Baril, R Leblanc, B Lebouche, J Cox, ... Clinical Infectious Diseases 62 (2), 250-257, 2016 | 80 | 2016 |
| HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 targets R Song, I Lisovsky, B Lebouché, JP Routy, J Bruneau, NF Bernard PLoS pathogens 10 (1), e1003867, 2014 | 79 | 2014 |
| Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: a systematic review N Kronfli, B Linthwaite, F Kouyoumdjian, MB Klein, B Lebouché, ... International Journal of Drug Policy 57, 95-103, 2018 | 68 | 2018 |
| A review of HIV-specific patient-reported outcome measures K Engler, D Lessard, B Lebouché The Patient-Patient-Centered Outcomes Research 10, 187-202, 2017 | 63 | 2017 |
| Cytomegalovirus seropositivity is associated with increased microbial translocation in people living with human immunodeficiency virus and uninfected controls R Ramendra, S Isnard, J Lin, B Fombuena, J Ouyang, V Mehraj, Y Zhang, ... Clinical Infectious Diseases 71 (6), 1438-1446, 2020 | 57 | 2020 |
| CXCL13 as a biomarker of immune activation during early and chronic HIV infection V Mehraj, R Ramendra, S Isnard, FP Dupuy, B Lebouché, C Costiniuk, ... Frontiers in immunology 10, 289, 2019 | 56 | 2019 |
| Incidence rate and risk factors for loss to follow‐up in a French clinical cohort of HIV‐infected patients from January 1985 to January 1998 B Lebouche, Y Yazdanpanah, Y Gerard, D Sissoko, F Ajana, I Alcaraz, ... HIV medicine 7 (3), 140-145, 2006 | 56 | 2006 |
| Plasma levels of C-type lectin REG3α and gut damage in people with human immunodeficiency virus S Isnard, R Ramendra, FP Dupuy, J Lin, B Fombuena, N Kokinov, I Kema, ... The Journal of infectious diseases 221 (1), 110-121, 2020 | 55 | 2020 |
| Telehealth and COVID-19 pandemic: an overview of the telehealth use, advantages, challenges, and opportunities during COVID-19 pandemic K Bouabida, B Lebouché, MP Pomey Healthcare 10 (11), 2293, 2022 | 54 | 2022 |
| Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection A Benmassaoud, P Ghali, J Cox, P Wong, J Szabo, M Deschenes, ... PLoS One 13 (1), e0191985, 2018 | 49 | 2018 |
| Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis A Amoako, D Ortiz-Paredes, K Engler, B Lebouché, MB Klein International Journal of Drug Policy 96, 103247, 2021 | 47 | 2021 |
Jean-Pierre RoutyMcGill University Health CentreVerified email at mcgill.ca
